Compare Bristol-Myers Squibb Co (BMY) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Garmin Ltd. — how do they compare? Bristol-Myers Squibb Co trades at $58.51 (market cap $116.30B), while Garmin Ltd. trades at $243.66 (market cap $46.55B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.5× Garmin Ltd.'s market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | GRMN | |
|---|---|---|
Market Cap | $116.30B | $46.55B |
Sector | Health | Technology |
52-Week High | $62.37 | $267.52 |
52-Week Low | $42.60 | $187.10 |
Enterprise Value | $152.24B | $44.02B |
Dividend Yield | 4.42% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Garmin (GRMN) trades at $243.61, up 0.21% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $7.25B in 2025, with a net income margin of 23.26%. Recent product launches, including AXIS flight displays and LiveScope 2 sonar, highlight innovation. The stock is near its pivot point of $243, with support at $242 and resistance at $245.
Outlook remains positive with a consensus price target of $282.67, implying 16% upside. Risks include competitive pressures in consumer electronics and aviation markets. Analyst sentiment is mixed, with 74% hold ratings, but earnings beats in recent quarters support growth trajectory. Dividend payments provide shareholder returns, with the next payment scheduled for September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
